Valeant Beats on All Fronts - Analyst Blog
05 Noviembre 2012 - 8:31AM
Zacks
Valeant Pharmaceuticals International’s
(VRX) third quarter 2012 earnings of $1.11 per share
(excluding special items but including stock-based compensation
expense) was above the Zacks Consensus Estimate of $1.09 and the
year-ago earnings of approximately 62 cents per share.
Revenues for the quarter were $884.1 million, up 47.2% from the
year-ago period. The year-over-year improvement in revenues was
primarily attributable to higher product sales. Revenues surpassed
the Zacks Consensus Estimate of $873 million.
Quarterly Highlights
Product sales at Valeant Pharma amounted to $856.9 million during
the third quarter of 2012, up 50%. Strong sales in the US
Dermatology and the Emerging Markets segments contributed to the
increase. Organically, (excluding the impact of acquisitions and
foreign exchange), revenues grew 12% from the year-ago quarter.
Research & development (R&D) expenses climbed 9.7% to $19.2
million. Selling, general & administrative (SG&A) expenses
for the third quarter of 2012 increased 40% to $188.7 million.
Guidance
Valeant Pharma adjusted its earnings guidance for fiscal 2012. Cash
earnings are now expected in the range of $4.60–$4.65 per share
(previous guidance: $4.55–$4.75 per share). Valeant continues to
expect total revenue in the range of $3.4 billion – $3.6 billion.
The Zacks Consensus Estimate for 2012 hints at earnings of $4.50
per share on revenues of $3.5 billion.
Cash earnings for the final quarter of 2012 are expected in the
range of $1.30-$1.35 per share (previous guidance: $1.25–$1.45 per
share). The guidance does not include new interest expense of 12
cents per share pertaining to Valeant’s impending acquisition of
Medicis Pharmaceutical Corporation (MRX). The
Zacks consensus Estimate for the fourth quarter of 2012 currently
stands at $1.31 per share.
Our Recommendation
We have a Neutral recommendation on Valeant Pharma. Valeant Pharma
carries a Zacks #4 Rank (Sell rating) in the short run.
MEDICIS PHARM-A (MRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Medicis (NYSE:MRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Medicis (NYSE:MRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Medicis Pharmaceutical Corp. (New York Stock Exchange): 0 recent articles
Más de Medicis Artículos de Noticias